<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00496379</url>
  </required_header>
  <id_info>
    <org_study_id>06-268</org_study_id>
    <nct_id>NCT00496379</nct_id>
  </id_info>
  <brief_title>ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases</brief_title>
  <official_title>A Phase 2 Study of ZK219477 (ZK-EPO) in Patients With Breast Cancer and Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nancy Lin, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Breast Cancer Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine the effects (good and bad) of
      ZK219477(sagopilone) on participants and their cancer. ZK219477 is a chemotherapy drug that
      is thought to work by interfering with the ability of cancer cells to grow and divide. It is
      a part of a group of drugs called &quot;epothilones&quot; which appear to cause shrinkage of cancer in
      some patients with breast cancer. It is generally difficult for chemotherapy to enter the
      brain. However, it is believed that ZK219477 crosses into the brain. We are also studying
      whether an investigational MRI scan procedure may eventually help to predict which patients
      will benefit from ZK219477.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Participants will be given ZK219477 intravenously over approximately 30 minutes every
           three weeks.

        -  During all treatment cycles a physical exam and questions about the participants general
           health and specific questions about any problems they may be having will be performed.

        -  At least every three weeks blood tests will be done to assess the effect of ZK219477 on
           the body.

        -  After every 2 cycles of treatment, participants will have additional scans to assess the
           effect of ZK219477 on their cancer. This will include a CT scan of the abdomen, chest,
           and pelvis, and an MRI of the brain.

        -  At the time of the standard MRI, participants will be asked to undergo an additional MRI
           sequence, which means they will be in the MRI machine for approximately 15-20 more
           minutes.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study has closed to accrual early due to slow accrual.
  </why_stopped>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate in the Central Nervous System (CNS)</measure>
    <time_frame>2 years</time_frame>
    <description>Objective response rate is defined as at least a 50 percent reduction in the Central Nervous system target lesion volume compared to the lesion volume at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Adverse Events (Any Grade)</measure>
    <time_frame>2 years</time_frame>
    <description>Adverse events per NCI CTCAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate in Non-Central Nervous System (CNS) Sites</measure>
    <time_frame>2 years</time_frame>
    <description>Non-CNS response rate (according to RECIST 1.0) limited to patients with measurable non-CNS disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression at Any Site.</measure>
    <time_frame>2 years</time_frame>
    <description>Time from date of registration until the date of the first documentation of progression or date of death (from any cause),whichever came first, up to 2 years from registration. Progression is defined as either progression in the Central Nervous system (CNS) according to volumetric measurement (Freedman et al. 2011) and /or progression in non-Central Nervous System lesion Measured by RECIST 1.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate.</measure>
    <time_frame>2 years</time_frame>
    <description>CBR = CR + PR + SD &gt; 24 weeks in CNS with at least stable non-CNS disease</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Breast Cancer</condition>
  <condition>CNS Disease</condition>
  <arm_group>
    <arm_group_label>ZK219477</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZK219477</intervention_name>
    <description>Given intravenously over approximately 30 minutes once every 3 weeks</description>
    <arm_group_label>ZK219477</arm_group_label>
    <other_name>ZK-EPO</other_name>
    <other_name>ZK-Epothilone</other_name>
    <other_name>Sagopilone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically or cytologically invasive breast cancer, with
             metastatic disease at the time of screening

          -  Measurable Central Nervous System (CNS) disease, as defined as at least one lesion &gt;
             or equal too 10mm in longest dimension

          -  New or progressive CNS lesions after at least one prior standard CNS-directed therapy
             for treatment of brain metastases, which could include surgical resection, whole brain
             radiotherapy (WBRT), and/or stereotactic radiosurgery (SRS). Patients must have
             received prior WBRT, SRS or both.

          -  Patient has been evaluated by a radiation oncologist, who feels that the plan to
             evaluate systemic chemotherapy in place of additional brain radiotherapy is an
             acceptable option

          -  No increase in corticosteroid use in the week prior to study entry

          -  Any number prior lines of chemotherapy for metastatic breast cancer

          -  18 years of age of older

          -  Life expectancy of greater than 12 weeks

          -  ECOG Performance Status 0-2

          -  Patients must have normal organ function as outlined in the protocol

        Exclusion Criteria:

          -  Patients who have had chemotherapy within 3 weeks prior to entering the study or those
             who have not recovered from adverse events due to agents administered more than 3
             weeks earlier

          -  Patients who have had XRT within 3 weeks prior to entering the study or those who have
             not recovered from adverse events due to XRT

          -  Patients may not be receiving any other investigational agent

          -  Patients may not be receiving any cancer-directed therapy

          -  Prior treatment with investigational chemotherapy for brain metastases

          -  Prior treatment with epothilone for metastatic breast cancer

          -  Leptomeningeal carcinomatosis as the only site of CNS involvement.

          -  Concurrent treatment with an enzyme inducing antiepileptic drug, including phenytoin,
             carbamezepine, phenobarbital, or oxacarbazepine

          -  More than 2 seizures over the last four weeks prior to study entry

          -  Known contraindication to MRI or gadolinium contrast, such as cardiac pacemaker,
             ocular foreign body, or shrapnel

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Pregnant or breastfeeding women.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2007</study_first_submitted>
  <study_first_submitted_qc>July 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2007</study_first_posted>
  <results_first_submitted>November 30, 2012</results_first_submitted>
  <results_first_submitted_qc>February 7, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 12, 2013</results_first_posted>
  <last_update_submitted>March 12, 2013</last_update_submitted>
  <last_update_submitted_qc>March 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Nancy Lin, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>metastatic breast cancer</keyword>
  <keyword>invasive breast cancer</keyword>
  <keyword>brain metastases</keyword>
  <keyword>ZK-EPO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Central Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epothilones</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled at Dana-Farber/Harvard Cancer Center between 8/1/2007-10/29/2009.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sagopilone</title>
          <description>Either 16 mg/m2 or 22 mg/m2 IV Q3W</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sagopilone</title>
          <description>Either 16 mg/m2 or 22 mg/m2 IV Q3W</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.3" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate in the Central Nervous System (CNS)</title>
        <description>Objective response rate is defined as at least a 50 percent reduction in the Central Nervous system target lesion volume compared to the lesion volume at baseline.</description>
        <time_frame>2 years</time_frame>
        <population>The study was closed prior to full accrual as detailed in the manuscript</population>
        <group_list>
          <group group_id="O1">
            <title>Sagopilone</title>
            <description>Either 16 mg/m2 or 22 mg/m2 IV Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate in the Central Nervous System (CNS)</title>
          <description>Objective response rate is defined as at least a 50 percent reduction in the Central Nervous system target lesion volume compared to the lesion volume at baseline.</description>
          <population>The study was closed prior to full accrual as detailed in the manuscript</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="2" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Adverse Events (Any Grade)</title>
        <description>Adverse events per NCI CTCAE</description>
        <time_frame>2 years</time_frame>
        <population>Study was closed prior to full accrual for reasons detailed in published manuscript</population>
        <group_list>
          <group group_id="O1">
            <title>Sagopilone</title>
            <description>Either 16 mg/m2 or 22 mg/m2 IV Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Events (Any Grade)</title>
          <description>Adverse events per NCI CTCAE</description>
          <population>Study was closed prior to full accrual for reasons detailed in published manuscript</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate in Non-Central Nervous System (CNS) Sites</title>
        <description>Non-CNS response rate (according to RECIST 1.0) limited to patients with measurable non-CNS disease</description>
        <time_frame>2 years</time_frame>
        <population>only included the 8 pts with measurable non-CNS disease at baseline. The 7 pts with non-measurable non-CNS disease at baseline were not included in the denominator for this endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Sagopilone</title>
            <description>Either 16 mg/m2 or 22 mg/m2 IV Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate in Non-Central Nervous System (CNS) Sites</title>
          <description>Non-CNS response rate (according to RECIST 1.0) limited to patients with measurable non-CNS disease</description>
          <population>only included the 8 pts with measurable non-CNS disease at baseline. The 7 pts with non-measurable non-CNS disease at baseline were not included in the denominator for this endpoint</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression at Any Site.</title>
        <description>Time from date of registration until the date of the first documentation of progression or date of death (from any cause),whichever came first, up to 2 years from registration. Progression is defined as either progression in the Central Nervous system (CNS) according to volumetric measurement (Freedman et al. 2011) and /or progression in non-Central Nervous System lesion Measured by RECIST 1.0</description>
        <time_frame>2 years</time_frame>
        <population>all patients who received at least 1 dose of protocol therapy</population>
        <group_list>
          <group group_id="O1">
            <title>Sagopilone</title>
            <description>Either 16 mg/m2 or 22 mg/m2 IV Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression at Any Site.</title>
          <description>Time from date of registration until the date of the first documentation of progression or date of death (from any cause),whichever came first, up to 2 years from registration. Progression is defined as either progression in the Central Nervous system (CNS) according to volumetric measurement (Freedman et al. 2011) and /or progression in non-Central Nervous System lesion Measured by RECIST 1.0</description>
          <population>all patients who received at least 1 dose of protocol therapy</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Benefit Rate.</title>
        <description>CBR = CR + PR + SD &gt; 24 weeks in CNS with at least stable non-CNS disease</description>
        <time_frame>2 years</time_frame>
        <population>all pts who received at least 1 dose of protocol therapy</population>
        <group_list>
          <group group_id="O1">
            <title>Sagopilone</title>
            <description>Either 16 mg/m2 or 22 mg/m2 IV Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit Rate.</title>
          <description>CBR = CR + PR + SD &gt; 24 weeks in CNS with at least stable non-CNS disease</description>
          <population>all pts who received at least 1 dose of protocol therapy</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sagopilone</title>
          <description>Either 16 mg/m2 or 22 mg/m2 IV Q3W</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Lymphocytes</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver Function Tests</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Bicarbonate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle/Joint Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Limb Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Generalized Weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic-other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neuropathy-Sensory</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Blurred/Double Vision</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Eye Pain/ Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neuropathy-Motor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nancy Lin</name_or_title>
      <organization>Dana-Farber Cancer Institute</organization>
      <phone>617-632-2335</phone>
      <email>nlin@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

